Technical Analysis for ZVSA - ZyVersa Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Slingshot Bearish | Bearish Swing Setup | 0.00% | |
| Bullish Engulfing | Bullish | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 21.08% | |
| New 52 Week Low | Weakness | 21.08% |
| Alert | Time |
|---|---|
| Gap Down Partially Closed | 1 day ago |
| Gap Down Closed | 1 day ago |
| 60 Minute Opening Range Breakout | 1 day ago |
| Up 1% | 1 day ago |
| Gapped Down (Partial) | 1 day ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address high unmet medical needs in the areas of renal and inflammatory diseases. ZyVersa's development pipeline includes phase 2a ready VAR 200, a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis. ZyVersa believes VAR 200 has potential to treat other glomerular diseases, including Alport syndrome and diabetic kidney disease. ZyVersa's development pipeline also includes IC 100, a novel inflammasome ASC inhibitor being developed to treat a multitude of inflammatory diseases.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Organ Systems Kidney Disease Inflammatory Diseases Kidney Diabetic Nephropathy Alport Syndrome Diabetic Kidney Disease Focal Segmental Glomerulosclerosis Glomerulosclerosis Inflammasome Stage Specialty Biopharmaceutical
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Organ Systems Kidney Disease Inflammatory Diseases Kidney Diabetic Nephropathy Alport Syndrome Diabetic Kidney Disease Focal Segmental Glomerulosclerosis Glomerulosclerosis Inflammasome Stage Specialty Biopharmaceutical
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 141.89 |
| 52 Week Low | 3.94 |
| Average Volume | 245,894 |
| 200-Day Moving Average | 20.31 |
| 50-Day Moving Average | 6.00 |
| 20-Day Moving Average | 4.94 |
| 10-Day Moving Average | 4.36 |
| Average True Range | 0.55 |
| RSI (14) | 49.24 |
| ADX | 24.35 |
| +DI | 23.15 |
| -DI | 21.66 |
| Chandelier Exit (Long, 3 ATRs) | 5.05 |
| Chandelier Exit (Short, 3 ATRs) | 5.58 |
| Upper Bollinger Bands | 6.33 |
| Lower Bollinger Band | 3.55 |
| Percent B (%b) | 0.5 |
| BandWidth | 56.27 |
| MACD Line | -0.48 |
| MACD Signal Line | -0.52 |
| MACD Histogram | 0.047 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.68 | ||||
| Resistance 3 (R3) | 6.54 | 5.83 | 6.39 | ||
| Resistance 2 (R2) | 5.83 | 5.38 | 5.90 | 6.29 | |
| Resistance 1 (R1) | 5.38 | 5.11 | 5.61 | 5.52 | 6.20 |
| Pivot Point | 4.67 | 4.67 | 4.78 | 4.74 | 4.67 |
| Support 1 (S1) | 4.22 | 4.22 | 4.45 | 4.36 | 3.68 |
| Support 2 (S2) | 3.51 | 3.95 | 3.58 | 3.59 | |
| Support 3 (S3) | 3.06 | 3.51 | 3.49 | ||
| Support 4 (S4) | 3.20 |
